8-甲基-1,4-二氧杂螺[4.5]癸-7-烯 | 33082-72-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 8-甲基-1,4-二氧杂螺[4.5]癸-7-烯
• 英文名称: 4-methyl-3-cyclohexen-1-one ethylene ketal
• 英文别名: 4,4-ethylenedioxy-1-methyl-1-cyclohexene；4-Methyl-3-cyclohexenon-aethylenketal；4,4-Aethylendioxy-1-methyl-1-cyclohexen；8-methyl-1,4-dioxa-spiro[4.5]dec-7-ene；8-Methyl-1,4-dioxaspiro[4.5]dec-7-ene
• CAS: 33082-72-3
• 化学式: C₉H₁₄O₂
• 分子量: 154.209
• InChiKey: OLHTUBJRPJSFJU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  8-甲基-1,4-二氧杂螺[4.5]癸-7-烯 在 硫酸 、 palladium on activated charcoal 、 氢气 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 4-甲基环己酮
  参考文献：
  名称：

  通过对映选择性对称化羰基-乙烯反应构建远距离立体中心

  摘要：

  因此，通过手性N，N'-二氧化物/ Ni II催化剂可以有效地使1-取代的4-亚甲基环己烷与乙二醛衍生物的羰基-烯键解对称，从而可以轻松地获得带有两个遥远的1,6-相关立体中心的环己烯衍生物。这种远端的立体控制方法源于催化剂与亲溶剂之间的有效相互作用，对烯烃组分的两个椅子构象的区分以及烯键过程的固有六元过渡态结构。

  DOI：

  10.1021/acs.orglett.7b01329
• 作为产物：
  描述：

  8-亚甲基-1,4-二噁螺[4.5]癸烷 在 palladium(II) trifluoroacetate 、 二苯基-2-吡啶膦 、 2-氟乙醇 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 24.0h， 以89%的产率得到8-甲基-1,4-二氧杂螺[4.5]癸-7-烯
  参考文献：
  名称：

  末端烯烃的Pd催化位点控制的异构化。

  摘要：

  描述了以2-PyPPh2作为配体的烯烃的有效Pd催化异构化。在温和的反应条件下，可以以高区域选择性和立体选择性获得具有各种官能团的各种反式-2-烯烃。配体对于反应至关重要。

  DOI：

  10.1021/acs.orglett.0c00168

文献信息

• SUBSTITUTED IMIDAZOHETEROCYCLES
  申请人：Beckett R. Paul

  公开号：US20080318935A1

  公开（公告）日：2008-12-25

  The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis and treatment of cannabinoid receptor-associated diseases and conditions, such as pain, inflammation and pruritis.

  本发明提供了具有式I结构的取代咪唑杂环化合物。还提供了式I化合物的药用可接受盐、酸盐、水合物、溶剂合物和立体异构体。这些化合物可用作大麻素受体调节剂，用于预防和治疗与大麻素受体相关的疾病和症状，如疼痛、炎症和瘙痒。
• NOVEL 3-(4(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE, METHOD OF PREPARING SAME AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC DISEASE INCLUDING SAME AS EFFECTIVE INGREDIENT
  申请人：HYUNDAI PHARM CO., LTD

  公开号：US20160024063A1

  公开（公告）日：2016-01-28

  The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient for the prevention and treatment of metabolic disease. The novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention has excellent activities of activating GPR40 protein and promoting insulin secretion accordingly but has no toxicity when co-administered with other drugs. That is, the novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention can be co-administered with other drugs and can promote the activation of GPR40 protein significantly, so that the composition comprising the same as an active ingredient can be efficiently used as a pharmaceutical composition for the prevention and treatment of metabolic disease such as obesity, type I diabetes, type II diabetes, incompatible glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X, etc.

  本发明涉及一种新型的3-(4-(苄氧基)苯基)己-4-羧酸衍生物，其制备方法以及包含该衍生物作为活性成分的药物组合物，用于预防和治疗代谢性疾病。本发明的这种新型的3-(4-(苄氧基)苯基)己-4-羧酸衍生物、其光学异构体或其药用可接受盐，对于激活GPR40蛋白并相应地促进胰岛素分泌具有优良活性，且在与其他药物联合使用时没有毒性。也就是说，本发明的这种新型的3-(4-(苄氧基)苯基)己-4-羧酸衍生物、其光学异构体或其药用可接受盐，可以与其他药物联合使用，并且能显著促进GPR40蛋白的激活，使得包含其作为活性成分的组合物能有效地用作预防和治疗诸如肥胖、I型糖尿病、II型糖尿病、糖耐量异常、胰岛素抵抗、高血糖、高脂血症、高甘油三酯血症、高胆固醇血症、血脂异常和X综合症等代谢性疾病的药物组合物。
• CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20110306592A1

  公开（公告）日：2011-12-15

  The present invention comprises compounds of Formula (I). wherein: R 1 , R 2 , X, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：R1、R2、X和Z如规范中所定义。该发明还包括一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病为II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• THERAPEUTIC COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20130281433A1

  公开（公告）日：2013-10-24

  Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.

  本文披露的化合物包括公式I′的化合物及其盐。还提供了包含本文披露的化合物的药物组合物、制备本文披露的化合物的方法、用于制备本文披露的化合物的中间体以及使用本文披露的化合物治疗HIV感染的治疗方法。
• PYRIDINE COMPOUND AND USE THEREOF
  申请人：NIPPON SODA CO., LTD.

  公开号：US20190071403A1

  公开（公告）日：2019-03-07

  The present invention provides a compound represented by formula (I) (in the formula, R 1 to R 4 each represent a hydrogen atom, an unsubstituted or G 1 -substituted C1-6 alkyl group or the like, A represents an oxygen atom or the like, Cy represents a C6-10 aryl group or the like), an N-oxide compound thereof, a tautomer or salt thereof. The present invention also provides an agricultural and horticultural fungicide, harmful organism control agent and insecticidal/acaricidal agent containing at least one compound selected from the group consisting of a compound represented by formula (I), a tautomer and salt thereof, as an active ingredient.

  本发明提供一种由式(I)表示的化合物（在该式中，R1至R4分别表示氢原子，未取代或G1取代的C1-6烷基或类似物，A表示氧原子或类似物，Cy表示C6-10芳基或类似物），其N-氧化物化合物，其互变异构体或盐。本发明还提供一种农业和园艺杀菌剂，有害生物控制剂和杀虫/杀螨剂，其含有从由式(I)表示的化合物、其互变异构体和盐中选择的至少一种化合物作为活性成分的组合。